In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections

被引:8
作者
Pierard, Denis [1 ]
Stone, Gregory G. [2 ]
机构
[1] Univ Ziekenhuis Brussel, Brussels, Belgium
[2] Pfizer Inc, 558 Eastern Point Rd, Groton, CT 06340 USA
关键词
ATLAS; beta-Haemolytic streptococci; Ceftaroline; Skin infection; Staphylococcus aureus; Surveillance; SOFT-TISSUE INFECTIONS; PENICILLIN-BINDING PROTEINS; STAPHYLOCOCCUS-AUREUS; COMPLICATED SKIN; UNITED-STATES; MANAGEMENT; PROGRAM; RESISTANCE; EUROPE; TRENDS;
D O I
10.1016/j.jgar.2021.04.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study reports the antimicrobial activities of ceftaroline and comparators against bacterial isolates from patients with skin and skin-structure infections (2015-2018). Methods: A central laboratory performed antimicrobial susceptibility testing according to CLSI broth microdilution methodology. EUCAST breakpoints were used. Results: Isolates were collected in Europe (14 408 isolates; 53.9%), Asia/South Pacific (SP) (5317; 19.9%), Latin America (4268; 16.0%) and Africa/Middle East (ME) (2753; 10.3%). In all regions, all 7950 methicillin-susceptible Staphylococcus aureus (MSSA) isolates were susceptible to ceftaroline and vancomycin; susceptibility to daptomycin, linezolid, teicoplanin and tigecycline was >= 99.6%. Susceptibility of all 9174 methicillin-resistant S. aureus (MRSA) isolates to daptomycin, linezolid, teicoplanin, tigecycline and vancomycin was >= 97.7%, with 90.8-96.5% susceptible to ceftaroline. The ceftaroline MIC 90 was 0.008 mg/L against Streptococcus pyogenes, 0.015-0.03 mg/L against Streptococcus agalactiae and 0.008-0.015 mg/L against Streptococcus dysgalactiae. All beta-haemolytic streptococci were susceptible to vancomycin. Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >= 96.7% in all regions. Susceptibility of ESBL-negative Klebsiella pneumoniae to ceftaroline ranged from 78.4% in Europe to 83.2% in Africa/ME, and among ESBL-negative Klebsiella oxytoca was 76.3% in Asia/SP and 89.0-93.5% in other regions. Among ESBL-negative K. pneumoniae and ESBL-negative K. oxytoca, susceptibility was highest to amikacin (93.7-96.4% and 95.7-100%, respectively) and meropenem (89.7-97.4% and 98.3-100%, respectively). Conclusion: Ceftaroline was active against the Gram-positive isolates collected. Susceptibility of ESBL-negative Gram-negative isolates showed regional variations. (C) 2021. Pfizer Inc. and the Author(s). Published by Elsevier.
引用
收藏
页码:4 / 10
页数:7
相关论文
共 50 条
[31]   Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012) [J].
Flamm, Robert K. ;
Farrell, David J. ;
Sader, Helio S. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2014, 78 (04) :449-456
[32]   Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Obese Patients [J].
Evans, John D. ;
Udeani, George ;
Cole, Phillip ;
Friedland, H. David .
POSTGRADUATE MEDICINE, 2014, 126 (05) :128-134
[33]   Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017-2020 [J].
Kiratisin, Pattarachai ;
Kempf, Marie ;
Stone, Gregory ;
Utt, Eric .
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2023, 34 :113-118
[34]   In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016-2018) [J].
Bae, In-Gyu ;
Stone, Gregory G. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 102 (01)
[35]   In vitro activity of ceftaroline against staphylococci from prosthetic joint infection [J].
Park, Kyung-Hwa ;
Greenwood-Quaintance, Kerryl E. ;
Patel, Robin .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 84 (02) :141-143
[36]   Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections [J].
Bhavnani, Sujata M. ;
Hammel, Jeffrey P. ;
van Wart, Scott A. ;
Rubino, Christopher M. ;
Reynolds, Daniel K. ;
Forrest, Alan ;
Drusano, George L. ;
Khariton, Tatiana ;
Friedland, David ;
Riccobene, Todd A. ;
Ambrose, Paul G. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) :372-380
[37]   In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections [J].
McCurdy, S. ;
Lawrence, L. ;
Quintas, M. ;
Woosley, L. ;
Flamm, R. ;
Tseng, C. ;
Cammarata, S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
[38]   Comparative in-vitro activity of ceftaroline against Staphylococcus aureus isolates from India [J].
Bakthavatchalam, Yamuna Devi ;
Pragasam, Agila Kumari ;
Anandan, Shalini ;
Joshi, Sangeeta ;
Chaudhuri, Bhaskar Naryanan ;
Chitnis, D. S. ;
Roy, Indranil ;
Tapan, Dhole ;
Veeraraghavan, Balaji .
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2016, 10 (01) :109-112
[39]   In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China [J].
Zhou, Menglan ;
Chen, Jingwei ;
Liu, Yali ;
Hu, Yunjian ;
Liu, Yingmei ;
Lu, Juan ;
Zhang, Shufang ;
Yu, Yunsong ;
Huang, Xun ;
Yang, Qing ;
Liao, Kang ;
Jin, Yan ;
Huang, Wenxiang ;
Feng, Xianju ;
Yang, Qiwen ;
Xu, Yingchun .
CLINICAL INFECTIOUS DISEASES, 2018, 67 :S206-S216
[40]   In Vitro Antimicrobial Activity of Quinolones Against Major Bacterial Isolates from the Ocular Surface Bacterial Flora of Tertiary Hospital Patients in Japan [J].
Eguchi, Hiroshi ;
Nishida, Koichi ;
Hotta, Fumika ;
Shimomura, Yoshikazu ;
Kusaka, Shunji .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 37 (02) :84-89